HLS Therapeutics Inc is facing a notable decline in its stock performance, raising concerns among investors.
HLS Therapeutics Inc (HLS.TO) is experiencing a downturn, with its stock sliding by 2.91% in today’s session. Investors are closely monitoring the situation as the company navigates its financial landscape.
Investor takeaway: The recent drop in HLS Therapeutics Inc's stock price highlights the volatility and uncertainty that can affect even established companies in the healthcare sector.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.85M
52W high
$5.76
52W low
$4.00
1W change
-4.76%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 81.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.26
+81.5% Upside
Current Price
C$4.00
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
28.8%
Annualized
90-Day Vol
23.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.35
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.77 | C$3.41 – C$4.16 |
| 60 trading days | C$3.55 | C$3.09 – C$4.09 |
| 90 trading days | C$3.35 | C$2.82 – C$3.97 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc Market Cap: CA$128.85 Million
Advertisement
With a market cap of CA$128.85 million, HLS Therapeutics is under pressure to demonstrate sustainable revenue growth to regain investor confidence.
Bull case
Despite the current decline, HLS Therapeutics has shown potential for growth, reporting a 15% increase in Vascepa net sales in its latest financial results.
Bear case
Today’s negative stock performance reflects investor concerns about the company’s profitability, highlighted by its negative profit margin of -18.46%.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
